In 2025, with the strong support of governments at all levels, investment institutions and industrial partners, T-MAXIMUM Biotech will continue to promote technological innovation and industrialization process, taking breakthrough universal CAR-T technology as the foundation.
[Yokohama, Japan - August 8, 2024] - At the highly anticipated 2024 ASCO Breakthrough Summit, T-MAXlMUNM Biotech, which focuses on the development of universal cell drugs, It has been highly praised by the international medical community for its pioneering achievements in the field of allogeneic CAR-T cell therapy.
On November 4th, the first event of the "Suzhou Biomedical Collaborative Innovation Enhancement Action Plan" - a symposium in the field of cell therapy - was successfully held.
On June 5, 2023, T-MAXIMUM Biotech (a biopharmaceutical company dedicated to the research and development of universal cell drugs) announced that The company independently developed and has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) (orphan drug Designation) The latest clinical progress of ODD's MT027 UCAR-T cell product for th…
On February 17, 2023, T-MAXIMUM Pharmaceutical (Suzhou) Co., LTD. (a subsidiary of "T-MAXIMUM Biotech ") announced that it had received an official written reply from the Office of Orphan Products Development (ODD) of the U.S. Food and Drug Administration (FDA). Its self-developed allogeneic generic CAR-T cell therapy product MT027 targeting B7-H3 has been granted Orp…